Document is current
Any future updates will be listed below
-
Authors
Nepal, Chirag https://orcid.org/0000-0001-8402-3805
Andersen, Jesper B. https://orcid.org/0000-0003-1760-5244
-
Funding
Funding for this research was provided by:
Sundhed og Sygdom, Det Frie Forskningsråd (6100-00557A)
- License Information
-
More Information
Article History
Received: 12 September 2022
Accepted: 24 April 2023
First Online: 11 May 2023
Competing interests
: J.B.A. declares consultancy roles for Flagship Pioneering, SEALD, and QED therapeutics. J.B.A. has received funding from Incyte. C.N. declares no competing interests.
